F
Flávio A. F. M. Bezerra
Researcher at Oswaldo Cruz Foundation
Publications - 11
Citations - 572
Flávio A. F. M. Bezerra is an academic researcher from Oswaldo Cruz Foundation. The author has contributed to research in topics: Knoevenagel condensation & Minimum inhibitory concentration. The author has an hindex of 9, co-authored 11 publications receiving 521 citations.
Papers
More filters
Journal ArticleDOI
Novel 1,2,3-triazole derivatives for use against Mycobacterium tuberculosis H37Rv (ATCC 27294) strain.
Nubia Boechat,Vitor F. Ferreira,Sabrina B. Ferreira,Maria de Lourdes G. Ferreira,Fernando de C. da Silva,Mônica M. Bastos,Marilia S. Costa,Maria C.S. Lourenço,Angelo C. Pinto,Antoniana U. Krettli,Anna Caroline Campos Aguiar,Brunno M Teixeira,Nathalia V da Silva,Priscila R. C. Martins,Flávio A. F. M. Bezerra,Ane Louise S Camilo,Gerson P. da Silva,Gerson P. da Silva,Carolina C. P. Costa +18 more
TL;DR: Derivatives of isoniazid (INH), (E)-N'-[(1-aryl)-1H-1,2,3-triazole-4-yl)methylene] isonicotinoyl hydrazides, exhibited significant activity and displayed low cytotoxicity against liver cells and kidney cells, thereby providing a high therapeutic index.
Journal ArticleDOI
Synthesis and antitubercular activity of palladium and platinum complexes with fluoroquinolones.
Lígia Maria Mendonça Vieira,Mauro V. de Almeida,Maria C.S. Lourenço,Flávio A. F. M. Bezerra,Ana Paula Soares Fontes +4 more
TL;DR: Aiming to obtain novel palladium( II) and platinum(II) complexes that exhibit biological activity, synthesized complexes using fluoroquinolones (ciprofloxacin, levofloxacIn, ofloxACin, sparfloxAcin, and gatifl oxacin) as ligands are synthesized.
Journal ArticleDOI
Synthesis and antitubercular activity of 7-chloro-4-quinolinylhydrazones derivatives
André L. P. Candéa,Marcelle de Lima Ferreira,Marcelle de Lima Ferreira,Karla C. Pais,Karla C. Pais,Laura N. F. Cardoso,Carlos R. Kaiser,Maria das Graças M. O. Henriques,Maria C.S. Lourenço,Flávio A. F. M. Bezerra,Marcus V. N. de Souza +10 more
TL;DR: The compounds 3f, 3i and 3o were non-cytotoxic and exhibited an important minimum inhibitory concentration (MIC) activity (2.5 microg/mL), which can be compared with that of the first line drugs, ethambutol and rifampicin.
Journal ArticleDOI
Mefloquine-oxazolidine derivatives, derived from mefloquine and arenecarbaldehydes: In vitro activity including against the multidrug-resistant tuberculosis strain T113.
Raoni S.B. Goncalves,Carlos R. Kaiser,Maria C.S. Lourenço,Flávio A. F. M. Bezerra,Marcus V. N. de Souza,Marcus V. N. de Souza,James L. Wardell,Solange M. S. V. Wardell,Maria das Graças M. O. Henriques,Thadeu Estevam Moreira Maramaldo Costa +9 more
TL;DR: The new mefloquine-oxazolidine derivatives have advantages over such anti-TB drugs as isoniazid, rifampicin, ethambutol and ofloxacin, for which this strain is resistant.
Journal ArticleDOI
Synthesis of α- and β-Pyran Naphthoquinones as a New Class of Antitubercular Agents
Sabrina Baptista Ferreira,Fernando de C. da Silva,Fernando de C. da Silva,Flávio A. F. M. Bezerra,Maria C.S. Lourenço,Carlos R. Kaiser,Angelo C. Pinto,Vitor F. Ferreira +7 more
TL;DR: Some naphthoquinones exhibited inhibition with MIC values of 1.25 μg/mL, similar to that of pharmaceutical concentrations currently used in tuberculosis treatment, justifying further research into the value of these quinones as part of an original treatment for tuberculosis.